MediPost Voluntarily Withdraws Combination Clinical Trial for Knee Osteoarthritis Treatment

"Focusing on Monotherapy Clinical Trials"

Medipost announced on the 2nd that it has voluntarily withdrawn the Phase 2 clinical trial in Japan combining the knee osteoarthritis treatment 'Cartistem' with high tibial osteotomy (HTO).

Medipost stated, "With the early approval of the Phase 3 clinical trial for (Cartistem) monotherapy, the significance of conducting the Phase 2 trial for the combination therapy simultaneously has diminished," adding, "We aimed to secure speed and business competitiveness by concentrating Japan's clinical research and development capabilities and funds on the Phase 3 clinical trial of Cartistem monotherapy."

Cartistem is a treatment approved by the Ministry of Food and Drug Safety in 2012 and is undergoing related clinical trials in the United States, Japan, and other countries. In Japan, Phase 3 clinical trials administering Cartistem alone and Phase 2 clinical trials combining Cartistem with HTO, a procedure that corrects bow-legged legs shaped like the letter 'O', were conducted simultaneously.